RXi Pharmaceuticals to Present at IBC's 15th Annual TIDES: Oligonucleotide and Peptide Therapeutics Conference

RXi Pharmaceuticals to Present at IBC's 15th Annual TIDES: Oligonucleotide and
                       Peptide Therapeutics Conference

PR Newswire

WESTBOROUGH, Mass., May 9, 2013

WESTBOROUGH, Mass., May 9, 2013 /PRNewswire/ --RXi Pharmaceuticals
Corporation (OTCQB: RXII), a biotechnology company focused on discovering,
developing and commercializing innovative therapies addressing major unmet
medical needs using RNA-targeted technologies, today announced that the
Company's Chief Development Officer, Pamela Pavco, Ph.D., will be presenting
at IBC's 15^th Annual TIDES: Oligonucleotide and Peptide Therapeutics
Conference. The TIDES Summit is prominently known as the premier meeting place
for the oligonucleotide and peptide discovery, development and manufacturing
industries.

On Wednesday, May 15, 2013 at 4:15pm EDT, Dr. Pavco will deliver a speaker
presentation entitled "Clinical Development of RXI-109 to Reduce Dermal
Scarring", during the Clinical Progress of Oligonucleotide Therapeutics
session. Dr. Pavco's presentation will be available on the Company's website.

This conference is being held May 12-15, 2013 at the Hynes Convention Center,
Boston, MA. For more information visit:
http://www.ibclifesciences.com/TIDES

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused
on discovering, developing and commercializing innovative therapies based on
its proprietary, self-delivering RNAi platform. Therapeutics that use RNA
interference, or "RNAi," have great promise because of their ability to
down-regulate, the expression of a specific gene that may be over-expressed in
a disease condition. Building on the pioneering work of scientific founder and
Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board,
RXi's first RNAi product candidate, RXI-109, targets connective tissue growth
factor (CTGF) to reduce dermal scarring (fibrosis), entered into human
clinical trials in June 2012. For more information, please visit
www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about future expectations, planned and
future development of RXi Pharmaceuticals Corporation's products and
technologies. Forward-looking statements about expectations and development
plans of RXi's products involve significant risks, and uncertainties: risks
that RXi may not be able to successfully develop its candidates, or that
development of RNAi-based therapeutics may be delayed or not proceed as
planned, or that we may not develop any RNAi-based product; risks that the
development process for our product candidates may be delayed, risks related
to development and commercialization of products by our competitors, risks
related to our ability to control timing and terms of collaborations with
third parties, and the possibility that other companies or organizations may
assert patent rights preventing us from developing our products. Actual
results may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur after the
date of this release.

Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com



SOURCE RXi Pharmaceuticals Corporation
 
Press spacebar to pause and continue. Press esc to stop.